Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PUR-WASH vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Sterile irrigation of body cavities, wounds, and surgical sites,Cleansing of wounds and burns,Rinsing of instruments and equipment,Hydration of tissues during surgical procedures
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.
250 mg orally twice daily
Terminal elimination half-life is 12-18 hours (mean 15 h). In patients with moderate renal impairment (Cr Cl 30-50 m L/min), half-life may extend to 24-30 hours; severe impairment (Cr Cl <30 m L/min) may prolong to >40 hours, requiring dose adjustment.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
PUR-WASH is not metabolized; it is absorbed and excreted unchanged by the kidneys if administered intravenously or absorbed from wounds. When used topically or for irrigation, minimal systemic absorption occurs.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal excretion of unchanged drug (85-90%), with 10-15% fecal elimination via biliary secretion.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein (AAG).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Vd = 0.3-0.5 L/kg, indicating moderate distribution into total body water; higher Vd observed in obesity (0.6 L/kg) due to lipophilicity.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 95-100% (first-pass metabolism negligible); Intramuscular: 100%; Subcutaneous: 90-95% (site-dependent).
70-90% (oral); 100% (IV).
No systemic absorption; not applicable.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
No systemic absorption; not applicable.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
No systemic absorption; use as directed for wound irrigation per local protocol.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
No systemic absorption; use as directed for wound irrigation per local protocol.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
For external use only. Not for injection. Use only if solution is clear and container undamaged. Discard unused portion. Do not use for irrigation of closed cavities without adequate drainage. Monitor fluid and electrolyte balance when large volumes are used, especially in patients with renal impairment or cardiac failure. Prolonged contact with tissues may cause maceration.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to any component. Do not use for irrigation of body cavities where absorption may lead to fluid overload or electrolyte disturbances without appropriate monitoring. Not for intravascular or intrathecal use.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
None relevant as PUR-WASH is a topical irrigating solution with no systemic absorption.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly needed. No specific trimester risks have been identified.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
It is unknown whether PUR-WASH is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No pharmacokinetic studies have been performed in pregnant women. Currently, no dose adjustment is recommended for PUR-WASH during pregnancy, but caution is warranted due to limited data.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
PUR-WASH is a sterile, preservative-free irrigating solution indicated for wound cleansing and debridement. Use at room temperature to avoid thermal injury. Do not use for prolonged irrigation of closed body cavities due to risk of fluid absorption. For external wounds only; not for injection or ophthalmic use.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Do not ingest or inject this solution; it is for external wound cleaning only.,Discard any unused portion after opening; do not reuse or store opened bottles.,Do not apply heat or microwave the solution to avoid burns.,Use within 24 hours of opening to maintain sterility.,If irritation or infection occurs, stop use and consult your healthcare provider.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PUR-WASH vs ALDOCLOR-250, answered by our medical review team.
PUR-WASH is a Irrigation Solution that works by PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PUR-WASH and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PUR-WASH is: Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PUR-WASH and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PUR-WASH is classified as Category C. PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly nee. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.